Federal Register / Vol. 87, No. 48 / Friday, March 11, 2022 / Notices 14023 

NCI Technology Transfer Center by 

email (richard.girards@nih.gov) or 

phone (240–276–6825). 

Intellectual Property 

E–003–2014: Agents That Specifically 

Bind Matrilin-3 and Their Use/Cartilage 

Targeting Agents and Their Use 

1. United States Provisional Patent 

Application No. 61/927,904, filed 15 

January 2014 (HHS Reference No. E– 

003–2014–0–US–01); 

2. United States Patent No. 

10,323,083, issued 18 June 2019 (HHS 

Reference No. E–003–2014–0–US–06); 

3. United States Patent No. 

10,954,291, issued 23 March 2021 (HHS 

Reference No. E–003–2014–0–US–07); 

4. United States Patent Application 

No. 17/177,644, filed 17 February 2021 

(HHS Reference No. E–003–2014–0–US– 

12); 

5. International Patent Application 

No. PCT/US2015/011433, filed 14 

January 2015 (HHS Reference No. E– 

003–2014–0–PCT–02); 

6. Australia Patent No. 2015206515, 

issued 26 March 2020 (HHS Reference 

No. E–003–2014–0–AU–03); 

7. Canada Patent Application No. 

2931005, filed 14 January 2015 (HHS 

Reference No. E–003–2014–0–CA–04); 

8. European Patent No. 3 094 350 B1, 

issued 04 March 2020 (HHS Reference 

No. E–003–2014–0–EP–05) and all of its 

national validations; 

9. European Patent Application No. 

19219282.1, filed 14 January 2015 (HHS 

Reference No. E–003–2014–0–EP–11); 

and 

10. any and all other U.S. and ex-U.S. 

patents and patent applications 

claiming priority to any one of the 

foregoing, now or in the future. 

The patent and patent application 

rights in these inventions have been 

assigned and/or exclusively licensed to 

the government of the United States of 

America. 

The prospective exclusive license 

territory may be worldwide and the 

fields of use may be limited to the 

following: The manufacture, 

distribution, sale and use of fusion 

proteins for the treatment of (a) growth 

disorders and (b) diseases of cartilage 

degeneration. 

These technologies disclose, e.g., 

monoclonal antibodies and antibody 

fragments that specifically bind to 

matrilin-3, conjugates including these 

molecules, and nucleic acid molecules 

encoding the antibodies, antigen 

binding fragments and conjugates. Also 

disclosed are compositions including 

the disclosed antibodies, antigen 

binding fragments, conjugates, and 

nucleic acid molecules. Methods of 

treating or inhibiting a cartilage disorder 

in a subject, as well as methods of 

increasing chondrogenesis in cartilage 

tissue are further provided. The 

methods can be used, for example, for 

treating or inhibiting a growth plate 

disorder in a subject, such as a skeletal 

dysplasia or short stature. 

This Notice is made in accordance 

with 35 U.S.C. 209 and 37 CFR 404. The 

prospective exclusive license will be 

royalty bearing, and the prospective 

exclusive license may be granted unless 

within fifteen (15) days from the date of 

this published Notice, the National 

Cancer Institute receives written 

evidence and argument that establishes 

that the grant of the license would not 

be consistent with the requirements of 

35 U.S.C. 209 and 37 CFR 404. 

In response to this Notice, the public 

may file comments or objections. 

Comments and objections, other than 

those in the form of a license 

application, will not be treated 

confidentially, and may be made 

publicly available. 

License applications submitted in 

response to this Notice will be 

presumed to contain business 

confidential information and any release 

of information from these license 

applications will be made only as 

required and upon a request under the 

Freedom of Information Act, 5 U.S.C. 

552. 

Dated: March 7, 2022. 

Richard U. Rodriguez, 

Associate Director, Technology Transfer 

Center, National Cancer Institute. 

[FR Doc. 2022–05140 Filed 3–10–22; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Center for Scientific Review; Notice of 

Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Advancing 

Gender Inclusive Excellence (AGIE)— 

Coordinating Center U54. 

Date: April 8, 2022. 

Time: 11:00 a.m. to 4:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive Bethesda, 

MD 20892, (Virtual Meeting). 

Contact Person: Shivani Sharma, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, 6701 Rockledge Drive, 

Bethesda, MD 20892, (240) 507–7661, 

shivani.sharma@nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Small 

Business: Initiative Research in Hematology. 

Date: April 11, 2022. 

Time: 2:00 p.m. to 8:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892, (Virtual Meeting). 

Contact Person: Larry Pinkus, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 4132, 

MSC 7802, Bethesda, MD 20892, (301) 435– 

1214, pinkusl@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Small 

Business: Endocrinology, Metabolism, 

Nutrition and Reproductive Sciences. 

Date: April 14, 2022. 

Time: 10:00 a.m. to 8:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892, (Virtual Meeting). 

Contact Person: Baskaran Thyagarajan, 

Ph.D., Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 800B, 

Bethesda, MD 20892, (301) 867–5309, 

thyagarajanb2@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Member 

Conflict: Virology. 

Date: April 15, 2022. 

Time: 10:00 a.m. to 7:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892, (Virtual Meeting). 

Contact Person: Kumud Singh, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, 6701 Rockledge Drive, 

Bethesa, MD 20892, (301) 761–7830, 

kumud.singh@nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.306, Comparative Medicine; 

93.333, Clinical Research, 93.306, 93.333, 

93.337, 93.393–93.396, 93.837–93.844, 

93.846–93.878, 93.892, 93.893, National 

Institutes of Health, HHS) 


lotter on DSK11XQN23PROD with NOTICES1
14024 Federal Register / Vol. 87, No. 48 / Friday, March 11, 2022 / Notices 

Dated: March 7, 2022. 

Tyeshia M. Roberson-Curtis, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2022–05139 Filed 3–10–22; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute on Drug Abuse; 

Notice of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute on 

Drug Abuse Special Emphasis Panel; NIDA L 

Conflict SEP. 

Date: March 29, 2022. 

Time: 11:00 a.m. to 12:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

National Institute on Drug Abuse, 301 North 

Stonestreet Avenue, Bethesda, MD 20892, 

(Virtual Meeting). 

Contact Person: Sheila Pirooznia, Ph.D., 

Scientific Review Officer, Division of 

Extramural Review, Scientific Review 

Branch, National Institute on Drug Abuse, 

NIH, 301 North Stonestreet Avenue, MSC 

6021, Bethesda, MD 20892, (301) 496–9350, 

sheila.pirooznia@nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.277, Drug Abuse Scientist 

Development Award for Clinicians, Scientist 

Development Awards, and Research Scientist 

Awards; 93.278, Drug Abuse National 

Research Service Awards for Research 

Training; 93.279, Drug Abuse and Addiction 

Research Programs, National Institutes of 

Health, HHS) 

Dated: March 7, 2022. 

Tyeshia M. Roberson-Curtis, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2022–05137 Filed 3–10–22; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Neurological 

Disorders and Stroke; Notice of Closed 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The contract proposals and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the contract 

proposals, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Neurological Disorders and Stroke Special 

Emphasis Panel; NINDS Contract Review. 

Date: April 4, 2022. 

Time: 11:30 a.m. to 5:00 p.m. 

Agenda: To review and evaluate contract 

proposals. 

Place: National Institutes of Health, 

Neuroscience Center, 6001 Executive 

Boulevard, Rockville, MD 20852 (Virtual 

Meeting). 

Contact Person: Marilyn Moore-Hoon, 

Ph.D., Scientific Review Officer, Scientific 

Review Branch, Division of Extramural 

Activities, National Institute of Neurological 

Disorders and Stroke, 6001 Executive 

Boulevard, Bethesda, MD 20892, 301–827– 

9087, mooremar@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.853, Clinical Research 

Related to Neurological Disorders; 93.854, 

Biological Basis Research in the 

Neurosciences, National Institutes of Health, 

HHS) 

Dated: March 7, 2022. 

Tyeshia M. Roberson-Curtis, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2022–05138 Filed 3–10–22; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HOMELAND 

SECURITY 

Coast Guard 

[Docket No. USCG–2022–0155] 

Information Collection Request to 

Office of Management and Budget; 

OMB Control Number: 1625–0122 

AGENCY: Coast Guard, DHS. 

ACTION: Sixty-day notice requesting 

comments. 

SUMMARY: In compliance with the 

Paperwork Reduction Act of 1995, the 

U.S. Coast Guard intends to submit an 

Information Collection Request (ICR) to 

the Office of Management and Budget 

(OMB), Office of Information and 

Regulatory Affairs (OIRA), requesting an 

extension of its approval for the 

following collection of information: 

1625–0122, Cargo Securing Manuals; 

without change. Our ICR describes the 

information we seek to collect from the 

public. Before submitting this ICR to 

OIRA, the Coast Guard is inviting 

comments as described below. 

DATES: Comments must reach the Coast 

Guard on or before May 10, 2022. 

ADDRESSES: You may submit comments 

identified by Coast Guard docket 

number [USCG–2022–0155] to the Coast 

Guard using the Federal eRulemaking 

Portal at https://www.regulations.gov. 

See the ‘‘Public participation and 

request for comments’’ portion of the 

SUPPLEMENTARY INFORMATION section for 

further instructions on submitting 

comments. 

A copy of the ICR is available through 

the docket on the internet at https://

www.regulations.gov. Additionally, 

copies are available from: Commandant 

(CG–6P), ATTN: Paperwork Reduction 

Act Manager, U.S. Coast Guard, 2703 

Martin Luther King Jr. Ave. SE, STOP 

7710, Washington, DC 20593–7710. 

FOR FURTHER INFORMATION CONTACT: A.L. 

Craig, Office of Privacy Management, 

telephone 202–475–3528, or fax 202– 

372–8405, for questions on these 

documents. 

SUPPLEMENTARY INFORMATION: 

Public Participation and Request for 

Comments 

This notice relies on the authority of 

the Paperwork Reduction Act of 1995; 

44 U.S.C. 3501 et seq., chapter 35, as 

amended. An ICR is an application to 

OIRA seeking the approval, extension, 

or renewal of a Coast Guard collection 

of information (Collection). The ICR 

contains information describing the 

Collection’s purpose, the Collection’s 

likely burden on the affected public, an 

explanation of the necessity of the 

Collection, and other important 

information describing the Collection. 

There is one ICR for each Collection. 

The Coast Guard invites comments on 

whether this ICR should be granted 

based on the Collection being necessary 

for the proper performance of 

Departmental functions. In particular, 

the Coast Guard would appreciate 

comments addressing: (1) The practical 


lotter on DSK11XQN23PROD with NOTICES1